HealthcareNSE · BSE

Sun Pharma Advanced Research Company Ltd.

SPARC · ISIN INE232I01014

Share price

₹233▲ +1.60%

Market capitalisation

₹7551 Cr● Closed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹7551 Cr

Current price

₹233

+1.60% today

52W high

₹249

52W low

₹108

Stock P/E

4.86

P/B ratio

5.64

02 · Per share & returns

EPS (TTM)

₹47.87

Book value

₹41.25

ROE

276.89%

ROA

79.22%

Dividend yield

0.00%

Beta

0.56

03 · Financials (TTM)

By the numbers

Revenue

₹39.15 Cr

+6716.80% YoY

EBITDA

₹1599 Cr

Net profit

₹1553 Cr

Profit margin

3967.30%

Operating margin

95.55%

Total debt

₹559 Cr

Total cash

₹1.16 Cr

Debt / equity

0.42x

Current ratio

2.47x

Payout ratio

0.00%

04 · Analyst view

Target price

—

Upside

—

Consensus

NONE

Analysts

—

05 · Shareholding pattern

Who owns SPARC?

Promoters
65.67%
Founders & promoter group
Institutions
2.37%
FII + DII
Public
31.96%
Retail & non-institutional

As of 19 May 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol: SPARC
Exchange: NSE · BSE
CIN: —
ISIN: INE232I01014
BSE code: 532872
Sector: Healthcare
Industry: Healthcare
Face value: ₹1
Listing date: 17 Jul 2007
Employees: —
Headquarters: Mumbai, India
Website: sparc.life

07 · About

What is Sun Pharma Advanced Research Company Ltd.?

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

08 · Common questions

Frequently asked

What is the CIN of Sun Pharma Advanced Research Company Ltd.?+

The Corporate Identity Number for Sun Pharma Advanced Research Company Ltd. is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Sun Pharma Advanced Research Company Ltd.?+

Promoter holding in SPARC is approximately 65.67%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Sun Pharma Advanced Research Company Ltd.?+

Sun Pharma Advanced Research Company Ltd. (SPARC) has a market capitalisation of approximately ₹7551 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent